Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients

Remark, Romain; Lupo, Audrey; Alifano, Marco; Biton, Jérôme; Ouakrim, Hanane; Stefani, Alessandro; Cremer, Isabelle; Goc, Jérémy; Régnard, Jean-François; Dieu-Nosjean, Marie-Caroline; Damotte, Diane

doi:10.1080/2162402x.2016.1255394

Cited by 74 publications

(67 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, high tumor islet/stromal macrophage ratio was significantly associated with longer DFS and OS (187). In a French study of 122 stage III-N2 NSCLC patients treated with cisplatin-based chemotherapy, no correlation of CD68+ TAMs with survival rates was found (188). These data indicated TAMs located in tumor nest (islets) as a favorable prognostic factor after platinum-containing chemotherapeutic treatment.…”

Section: Tams and Lung Cancer Treatmentmentioning

confidence: 98%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to 50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate from resident tissue-specific macrophages and from newly recruited monocytes. TAMs' variability strongly depends on cancer type, stage, and intratumor heterogeneity. Majority of TAMs are programmed by tumor microenvironment to support primary tumor growth and metastatic spread. However, TAMs can also restrict tumor growth and metastasis. In this review, we summarized the knowledge about the role of TAMs in tumor growth, metastasis and in the response to cancer therapy in patients with five aggressive types of cancer: breast, colorectal, lung, ovarian, and prostate cancers that are frequently metastasize into distant organs resulting in high mortality of the patients. Two major TAM parameters are applied for the evaluation of TAM correlation with the cancer progression: total amount of TAMs and specific phenotype of TAMs identified by functional biomarkers. We summarized the data generated in the wide range of international patient cohorts on the correlation of TAMs with clinical and pathological parameters of tumor progression including lymphatic and hematogenous metastasis, recurrence, survival, therapy efficiency. We described currently available biomarkers for TAMs that can be measured in patients' samples (tumor tissue and blood). CD68 is the major biomarker for the quantification of total TAM amounts, while transmembrane receptors (stabilin-1, CD163, CD206, CD204, MARCO) and secreted chitinase-like proteins (YKL-39, YKL-40) are used as biomarkers for the functional TAM polarization. We also considered that specific role of TAMs in tumor progression can depend on the localization in the intratumoral compartments. We have made the conclusion for the role of TAMs in primary tumor growth, metastasis, and therapy sensitivity for breast, colorectal, lung, ovarian, and prostate cancers. In contrast to other cancer types, majority of clinical studies indicate that TAMs in colorectal cancer have protective role for the patient and interfere with primary tumor growth

show abstract

Section: Tams and Lung Cancer Treatmentmentioning

confidence: 98%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the Kras LSL−G12D/+ Trp53 −/− (KP) genetically engineered mouse model of lung cancer, hypo-fractionated radiotherapy induces an early reduction in TLS densities followed by their restoration within 2 weeks 119 . Two independent studies of human NSCLC reported that TLSs present in lesions regressing after neoadjuvant anti-PD1 therapy 30 or chemotherapy 120 were associated with longer disease-free survival and overall survival 120 . By contrast, caution should be taken with using associated therapies, such as corticosteroids, often used to manage the side effects of chemotherapy, as they have been reported to decrease TLS density in lung squamous cell carcinoma and to impair the positive clinical impact 60 .…”

Section: Therapeutic Modulation Of Tlss and Its Impact On Clinical Oumentioning

confidence: 99%

Tertiary lymphoid structures in the era of cancer immunotherapy

2019

View full text Add to dashboard Cite

Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis have been identified. TLSs exist under different maturation states in tumours, culminating in germinal centre formation. The mechanisms that underlie the role of TLSs in the adaptive antitumour immune response are being deciphered. The description of the correlation between TLS presence and clinical benefit in patients with cancer, suggesting that TLSs could be a prognostic and predictive factor, has drawn strong interest into investigating the role of TLSs in tumours. A current major challenge is to exploit TLSs to promote lymphocyte infiltration, activation by tumour antigens and differentiation to increase the antitumour immune response. Several approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic scaffolds to induce TLS formation. Strategies aiming to induce TLS neogenesis in immune-low tumours and in immune-high tumours, in this case, in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors, represent promising avenues for cancer treatment.

show abstract

“…However, the widespread use of these treatments has been implemented mostly on empirical (rather than immunological) grounds. 200,[296][297][298][299][300] Indeed, the possibility that chemotherapy and other forms of treatment (including radiotherapy and photodynamic therapy) might promote an immunogenic form of cancer cell death has been overlooked for several decades. [301][302][303] Thus, current anticancer drugs have been developed in immunodeficient preclinical models and in clinical trials devoid of any form of immunomonitoring, mainly most often aimed at identifying maximum tolerated doses (MTDs).…”

Section: Discussionmentioning

confidence: 99%

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

et al. 2017

View full text Add to dashboard Cite

The expression "immunogenic cell death" (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as "damage-associated molecular patterns". Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.

show abstract

Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients

Cited by 74 publications

References 38 publications

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

Tertiary lymphoid structures in the era of cancer immunotherapy

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

Contact Info

Product

Resources

About